Table 2 Mean baseline spirometry according to bronchodilator responsiveness status.
From: Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial
Criterion A (∆ % Predicted FEV1≥12% and ≥200 mL) | Criterion B (∆ % Predicted FEV1≥15%) | Criterion C (∆ % Predicted FEV1≥10%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nonresponder (n = 2750) | Responder (n = 3033) | Nonresponder (n = 1995) | Responder (n = 3788) | Nonresponder (n = 3553) | Responder (n = 2230) | |||||||
Tio (n = 1357) | Placebo (n = 1393) | Tio (n = 1520) | Placebo (n = 1513) | Tio (n = 995) | Placebo (n = 1000) | Tio (n = 1882) | Placebo (n = 1906) | Tio (n = 1769) | Placebo (n = 1784) | Tio (n = 1108) | Placebo (n = 1122) | |
Prebronchodilator | ||||||||||||
FEV1 (L) | 1.09 ± 0.45 | 1.07 ± 0.43 | 1.11 ± 0.36 | 1.11 ± 0.37 | 1.29 ± 0.44 | 1.25 ± 0.42 | 1.00 ± 0.34 | 1.01 ± 0.36 | 1.12 ± 0.43 | 1.10 ± 0.43 | 1.08 ± 0.35 | 1.07 ± 0.36 |
FEV1 % predicted | 40.7 ± 13.4 | 40.0 ± 13.2 | 38.5 ± 10.6 | 38.6 ± 10.5 | 45.6 ± 12.2 | 44.8 ± 12.3 | 36.3 ± 10.6 | 36.3 ± 10.6 | 39.9 ± 13.1 | 39.6 ± 13.0 | 38.9 ± 10.1 | 38.8 ± 10.0 |
FVC (L) | 2.57 ± 0.86 | 2.54 ± 0.85 | 2.69 ± 0.76 | 2.71 ± 0.80 | 2.84 ± 0.85 | 2.81 ± 0.84 | 2.52 ± 0.76 | 2.53 ± 0.81 | 2.65 ± 0.83 | 2.63 ± 0.84 | 2.59 ± 0.76 | 2.61 ± 0.81 |
Postbronchodilator | ||||||||||||
FEV1 (L) | 1.19 ± 0.44 | 1.16 ± 0.43 | 1.46 ± 0.39 | 1.46 ± 0.40 | 1.36 ± 0.47 | 1.33 ± 0.45 | 1.31 ± 0.42 | 1.32 ± 0.44 | 1.25 ± 0.44 | 1.23 ± 0.44 | 1.46 ± 0.40 | 1.46 ± 0.41 |
FEV1 % predicted | 44.4 ± 13.3 | 43.7 ± 13.1 | 50.8 ± 11.3 | 50.9 ± 11.1 | 48.3 ± 13.0 | 47.5 ± 13.1 | 47.5 ± 12.6 | 47.4 ± 12.4 | 44.6 ± 12.9 | 44.2 ± 12.9 | 52.9 ± 10.5 | 52.6 ± 10.3 |
% ∆ FEV1 | 10.9 ± 10.2 | 11.1 ± 10.4 | 34.6 ± 16.0 | 34.7 ± 15.9 | 6.14 ± 6.65 | 6.16 ± 6.82 | 32.6 ± 15.2 | 32.4 ± 15.2 | 13.8 ± 11.2 | 13.8 ± 11.5 | 38.7 ± 16.1 | 38.6 ± 15.7 |
FVC (L) | 2.81 ± 0.84 | 2.79 ± 0.85 | 3.36 ± 0.80 | 3.38 ± 0.86 | 3.02 ± 0.87 | 3.00 ± 0.88 | 3.14 ± 0.86 | 3.15 ± 0.91 | 2.97 ± 0.85 | 2.95 ± 0.87 | 3.30 ± 0.85 | 3.33 ± 0.90 |
GOLD Stage (%) | ||||||||||||
II | 37.4 | 34.2 | 55.9 | 56.9 | 49.8 | 46.6 | 45.7 | 45.7 | 37.0 | 35.8 | 63.4 | 62.2 |
III | 48.0 | 50.5 | 41.2 | 39.7 | 41.1 | 43.3 | 46.1 | 45.6 | 50.1 | 50.2 | 35.2 | 36.4 |
IV | 14.7 | 15.4 | 2.8 | 3.4 | 9.0 | 10.1 | 8.0 | 8.6 | 12.9 | 14.0 | 1.2 | 1.3 |